alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Editorial Note on Part 172
Editorial Note: Nomenclature changes to part 172 appear at 61 FR 14482, Apr. 2, 1996; 66 FR 56035, Nov. 6, 2001; 66 FR 66742, Dec. 27, 2001; 68 FR 15355, Mar. 31, 2003; 70 FR 40880, July 15, 2005; 70 FR 67651, Nov. 8, 2005; 70 FR 72074, Dec. 1, 2005; and 81 FR 49896, July 29, 2016.

§ 172.829 Neotame. ( a ) Neotame is the chemical *N*-[*N*-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine-1-methyl ester (CAS Reg. No. 165450-17-9).
( b ) Neotame meets the following specifications when it is tested according to the methods described or referenced in the document entitled “Specifications and Analytical Methods for Neotame” dated April 3, 2001, by the NutraSweet Co., 699 North Wheeling Rd., Mount Prospect, IL 60056. The Director of the Office of the Federal Register has approved the incorporation by reference of this material in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies are available from the Office of Food Additive Safety (HFS-200), Center for Food Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus Dr., College Park, MD 20740, 240-402-1200. Copies may be examined at the Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852, 240-402-7500, between 9 a.m. and 4 p.m., Monday through Friday, or at the National Archives and Records Administration (NARA). For information on the availability of this material at NARA, call 202-741-6030, or go to: *http://www.archives.gov/federal_register/code_of_federal_regulations/ibr_locations.html .* ( 1 ) Assay for neotame, not less than 97.0 percent and not more than 102.0 percent on a dry basis.
( 2 ) Free dipeptide acid (*N*-[*N*-(3,3-dimethylbutyl)-L-α-aspartyl]-L-phenylalanine), not more than 1.5 percent.
( 3 ) Other related substances, not more than 2.0 percent.
( 4 ) Lead, not more than 2.0 milligrams per kilogram.
( 5 ) Water, not more than 5.0 percent.
( 6 ) Residue on ignition, not more than 0.2 percent
( 7 ) Specific rotation, determined at 20 °C [α]D: −40.0° to 43.4° calculated on a dry basis.
( c ) The food additive neotame may be safely used as a sweetening agent and flavor enhancer in foods generally, except in meat and poultry, in accordance with current good manufacturing practice, in an amount not to exceed that reasonably required to accomplish the intended technical effect, in foods for which standards of identity established under section 401 of the Federal Food, Drug, and Cosmetic Act do not preclude such use.
( d ) When neotame is used as a sugar substitute tablet, L-leucine may be used as a lubricant in the manufacture of tablets at a level not to exceed 3.5 percent of the weight of the tablet.
( e ) If the food containing the additive purports to be or is represented to be for special dietary use, it shall be labeled in compliance with part 105 of this chapter.
[67 FR 45310, July 9, 2002, as amended at 81 FR 5591, Feb. 3, 2016; 88 FR 17721, Mar. 24, 2023]
Exhibit 32.1



CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the accompanying Quarterly Report of Wellman, Inc. (the "Company") on Form 10-Q for the period ended June 30, 2003 as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Thomas M. Duff, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. section 1350, as adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:

1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.







|By/s/Thomas M. Duff__
Chief Executive Officer
|---------------------------------------------
H. Res. 645 

In the House of Representatives, U. S., 

December 6, 2017. 

Resolved, That upon adoption of this resolution it shall 

be in order to consider in the House the bill (H.R. 38) to 

amend title 18, United States Code, to provide a means by 

which nonresidents of a State whose residents may carry concealed firearms may also do so in the State. All points of 

order against consideration of the bill are waived. In lieu of 

the amendment in the nature of a substitute recommended by 

the Committee on the Judiciary now printed in the bill, an 

amendment in the nature of a substitute consisting of the 

text of Rules Committee Print 115–45 shall be considered as 

adopted. The bill, as amended, shall be considered as read. 

All points of order against provisions in the bill, as amended, 

are waived. The previous question shall be considered as ordered on the bill, as amended, and on any further amendment 

thereto, to final passage without intervening motion except: 

(1) one hour of debate equally divided and controlled by the 

chair and ranking minority member of the Committee on the 
2 

•HRES 645 EH 

Judiciary; and (2) one motion to recommit with or without 

instructions. 

Attest: 

Clerk.
### I N THE UNI TED STATES COURT OF APPEALS FOR THE FI F TH CI RCUI T

No. 12-50766 Summary Calendar
UNITED STATES OF AMERICA, Plaintiff-Appellee

v. JAVIER CABRERA MOYA, Defendant-Appellant

A ppeal from the United States District Court for the Western District of Texas USDC No. 5:11-CR-406-1
Before KING, CLEMENT, and HIGGINSON, Circuit Judges. PER CURIAM: * The Federal Public Defender appointed to represent Javier Cabrera Moya has moved for leave to withdraw and has filed a brief in accordance with Anders

v. C alifornia , 386 U.S. 738 (1967), and United S tates v . F lores , 632 F.3d 229 (5th Cir. 2011). Cabrera Moya has not filed a response. We have reviewed c ounsel’s brief and the relevant portions of the record reflected therein. We concur with

c o u n s e l ’ s a s s e s s m e n t that the appeal presents no nonfrivolous issue for appellate review. Accordingly, counsel’s motion for leave t o withdraw is GRANTED, U n i t e d S t a te s C o u r t o f A p p e al s

F i f t h C i rc u i t 

### F I L E D April 12, 2013 Ly l e W . Cay ce Clerk

* Purs uant to 5 T H C I R
. R

. 47. 5, the court has d eterm ined that this op inion should not be p ublis hed and is not p reced ent excep t und er the lim ited circum s tances s et forth in 5 T H C I R
. R. 47. 5. 4. Case: 12-50766 Document: 00512206963 Page: 1 Date Filed: 04/12/2013No. 12-50766

counsel is excused from further responsibilities he r e i n, and the APPEAL IS DISMISSED. See 5 T H C I R
. R. 42.2.

2 Case: 12-50766 Document: 00512206963 Page: 2 Date Filed: 04/12/2013
EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of National Medical Health Card Systems, Inc. (the Company) on
Form 10-Q for the period ended September 30, 2006 as filed with the Securities and Exchange Commission on the date hereof (the Report), I, James F. Smith, President and Chief Executive Officer of the Company, certify, pursuant to 18
U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1) the Report fully
complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

(2) the information
contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.



|                                                                   
|-------------------------------------------------------------------
|                                                                   
|/s/ James F. Smith                                                 
|James F. Smith                                                     
|President and Chief Executive Officer (Principal Executive Officer)
|Date: March 7, 2007                                                

This certification accompanies this Report on Form 10-Q pursuant to Section 906 of the Sarbanes-Oxley Act of
2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act). Such certification will not be deemed to
be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.
###### Editorial Note on Part 181

#### Editorial Note:

Nomenclature changes to part 181 appear at 61 FR 14482, Apr. 2, 1996, and 66 FR 56035, Nov. 6, 2001.

#### § 181.27 Plasticizers.

Substances classified as plasticizers, when migrating from food-packaging material shall include:

Acetyl tributyl citrate.

Acetyl triethyl citrate.

*p-tert-*Butylphenyl salicylate.

Butyl stearate.

Butylphthalyl butyl glycolate.

Dibutyl sebacate.

Di-(2-ethylhexyl) phthalate (for foods of high water content only).

Diethyl phthalate.

Diisobutyl adipate.

Diisooctyl phthalate (for foods of high water content only).

Diphenyl-2-ethylhexyl phosphate.

Epoxidized soybean oil (iodine number maximum 6; and oxirane oxygen, minimum, 6.0 percent).

Ethylphthalyl ethyl glycolate.

Glycerol monooleate.

Monoisopropyl citrate.

Mono, di-, and tristearyl citrate.

Triacetin (glycerol triacetate).

Triethyl citrate.

3-(2-Xenolyl)-1,2-epoxypropane.

[42 FR 14638, Mar. 15, 1977; 42 FR 56728, Oct. 28, 1977, as amended at 50 FR 49536, Dec. 3, 1985]
§ 1.1162 What are the consequences if FDA puts a LAAF-accredited laboratory on probation or disqualifies a LAAF-accredited laboratory? ( a ) A LAAF-accredited laboratory that FDA has put on probation for one or more methods is permitted to continue to conduct food testing under this subpart; however, a LAAF-accredited laboratory that is on probation for one or more methods is not permitted to submit abridged analytical reports for the major food testing discipline of which the probationary methods are part.
( b ) If FDA disqualifies a LAAF-accredited laboratory for all methods within its scope of LAAF-accreditation, the laboratory is immediately ineligible to conduct food testing under this subpart. If FDA disqualifies a LAAF-accredited laboratory for specific methods within the scope of LAAF-accreditation, the laboratory is immediately ineligible to use the methods for which the laboratory has been disqualified to conduct food testing under this subpart.
( c ) With respect to food testing conducted by the laboratory prior to its disqualification, FDA may refuse to consider results and associated reports of food testing conducted under this subpart if the basis for the disqualification of the laboratory indicates that the specific food testing conducted by the laboratory may not be reliable.
( d ) Within 10 business days of the date of issuance of disqualification, the laboratory must provide the name and email address of the custodian who will maintain and make available to FDA the records required by § 1.1154, and the street address where the records will be located.
( e ) Within 10 business days of the date of issuance of a notice of probation or disqualification, the laboratory must notify any owners or consignees for which it is conducting food testing using methods for which it is being placed on probation or disqualified under this subpart, that it is on probation or has been disqualified.
No. 76-545.

#### United Airlines, Inc. *v.*McDonald.

C. A. 7th Cir. Certiorari granted.

Mr. Justice Stevens took no part in the consideration or decision of this petition.
§ 16.80 Administrative record of a regulatory hearing. ( a ) The administrative record of the regulatory hearing consists of the following: ( 1 ) The notice of opportunity for hearing and the response.
( 2 ) All written information and views submitted to the presiding officer at the hearing or after if specifically permitted by the presiding officer.
( 3 ) Any transcript of the hearing.
( 4 ) The presiding officer's report of the hearing and comments on the report under § 16.60(e).
( 5 ) All letters and memoranda of meetings or communications between participants and the presiding officer or the Commissioner referred to in § 16.44(c).
( b ) The record of the regulatory hearing is closed to the submission of information and views, at the close of the hearing, unless the presiding officer specifically permits additional time for a further submission.
```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[S. 1156 Introduced in Senate (IS)]

<DOC>

115th CONGRESS
  1st Session
                                S. 1156

  To amend the Internal Revenue Code of 1986 to allow rehabilitation 
expenditures for public school buildings to qualify for rehabilitation 
                                credit.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                              May 17, 2017

 Mr. Kaine (for himself and Mr. Warner) introduced the following bill; 
     which was read twice and referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
  To amend the Internal Revenue Code of 1986 to allow rehabilitation 
expenditures for public school buildings to qualify for rehabilitation 
                                credit.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``School Infrastructure Modernization 
Act of 2017''.

SEC. 2. QUALIFICATION OF REHABILITATION EXPENDITURES FOR PUBLIC SCHOOL 
              BUILDINGS FOR REHABILITATION CREDIT.

    (a) In General.--Section 47(c)(2)(B)(v) of the Internal Revenue 
Code of 1986 is amended by adding at the end the following new 
subclause:
                                    ``(III) Clause not to apply to 
                                public schools.--This clause shall not 
                                apply in the case of any building which 
                                is a qualified public educational 
                                facility (as defined in section 
                                142(k)(1), determined without regard to 
                                subparagraph (B) thereof) and used as 
                                such during some period before such 
                                expenditure and used as such 
                                immediately after such expenditure.''.
    (b) Report.--Not later than the date which is 5 years after the 
date of the enactment of this Act, the Secretary of the Treasury, after 
consultation with the heads of appropriate Federal agencies, shall 
report to Congress on the effects resulting from the amendment made by 
subsection (a).
    (c) Effective Date.--The amendment made by this section shall apply 
to property placed in service after the date of the enactment of this 
Act.
                                 <all>
```
<PAGE> 1
                                                                     EXHIBIT B
                                    WATERHOUSE INVESTOR SERVICES, INC.
                            COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES



<TABLE>
                              
                                                 Fiscal Years Ended August 31,                     
                                 --------------------------------------------------------------   First Quarter                    
                                                                                                   Fiscal Year
                                    1991        1992         1993         1994          1995          1996    
                                 ----------  -----------  -----------  -----------  -----------    -----------
<S>                             <C>         <C>          <C>          <C>           <C>            <C>  
Earnings Before Taxes On Income  $5,689,134  $15,163,052  $25,791,806  $28,009,177  $33,447,304    $11,258,362
                                 ----------  -----------  -----------  -----------  -----------    -----------

Fixed Charges:      
   Interest                       1,388,577    1,958,817    3,043,570    5,791,799   11,805,775      6,961,042
   Interest Factor in Rent          418,685      618,012      899,371    1,206,530    1,433,164        450,544
                                  ---------    ---------    ---------    ---------   ----------      ---------
   Total Fixed Charges            1,807,262    2,576,829    3,942,941    6,998,329   13,238,939      7,411,586
                                  ---------    ---------    ---------    ---------   ----------      ---------

Earnings Before Taxes On Income
   and Fixed Charges             $7,496,396  $17,739,881  $29,734,747  $35,007,506  $46,686,243    $18,669,948
                                 ==========  ===========  ===========  ===========  ===========    ===========

Ratio Of Earnings to Fixed 
   Charges                             4.15         6.88         7.54         5.00         3.53           2.52

</TABLE>
IV 

115TH CONGRESS 

1ST SESSION H. RES. 587 

Expressing the sense of the House of Representatives that the deduction 

for State and local taxes is beneficial and should remain intact. 

IN THE HOUSE OF REPRESENTATIVES 

OCTOBER 25, 2017 

Ms. ESTY of Connecticut (for herself, Mr. COURTNEY, Ms. DELAURO, Mr. 

LARSON of Connecticut, and Mr. HIMES) submitted the following resolution; which was referred to the Committee on Ways and Means 

RESOLUTION 

Expressing the sense of the House of Representatives that 

the deduction for State and local taxes is beneficial and 

should remain intact. 

Whereas the deduction for State and local taxes is a fundamental cornerstone of American fiscal federalism; 

Whereas eliminating the deduction for State and local taxes 

would increase taxes for approximately 24 percent of taxpayers nationwide; 

Whereas the deduction for State and local taxes helps State 

and local governments fund K-12 education, economic development, job training, transportation, health care, police, fire, parks, libraries, community health facilities, and 

first responders, all of which would be at risk if the deduction were eliminated; 


lotter on DSKBCFDHB2PROD with BILLS
2 

•HRES 587 IH 

Whereas using the sum of property tax (real estate tax and 

personal property tax), corporate income tax, and the 

greater of individual income tax or general sales tax as 

a rough measure of potentially deductible taxes, the potentially deductible portion of State and local taxes was 

about 32 percent of general revenues overall in 2013; and 

Whereas 60 percent of taxpayers making less than $50,000 

a year claim the State and local tax deduction for their 

local property taxes: Now, therefore, be it 

1 Resolved, That it is the sense of the House of Rep2 resentatives that the deduction for State and local taxes 

3 is beneficial to American taxpayers and should remain in4 tact. 

Æ 


lotter on DSKBCFDHB2PROD with BILLS
#### § 1313.03 Forms applicable to this part.

| Form | Access/ submission |
| --- | --- |
| DEA Form 486, Import/Export Declaration for List I and List II Chemicals | electronic. |
| DEA Form 486A Import Declaration for ephedrine, pseudoephedrine, and phenylpropanolamine (including drug products containing these chemicals) | electronic. |

[[81 FR 97036](https://www.federalregister.gov/citation/81-FR-97036), Dec. 30, 2016]
exv10w5



 







Exhibit 10.5




SCHEDULE OF EMPLOYEES PARTY TO



EMPLOYMENT AGREEMENT (SENIOR VICE PRESIDENT — VERSION 2)



Each of the executive officers of Comerica Incorporated named below executed an Employment
Agreement on the date set forth across from his or her name.




	 	 	 
	Executive Officer	 	Date of Agreement
	 
	Robert D. McDermott

	 	August 1, 2006
Exhibit 10.30  



	[EntreMed Logo]	 	www.entremed.com




February 28,
2006 


Affymax, Inc.

4001 Miranda Avenue

Palo Alto, California 94304

Attn: Robert Naso, Ph.D.

          Executive Vice President, R&D 


Re:     Third Extension of Letter Agreement


Dear
Bob: 


        I
am writing with reference to the Letter Agreement between Affymax, Inc. ("Affymax") and EntreMed, Inc. ("EntreMed") dated as of September 20, 2004 (together with
each of the exhibits thereto, the "Letter Agreement") and the related First Extension Letter dated as of August 23, 2005 between Affymax and EntreMed (the "First Extension Letter"),
pursuant to which EntreMed and Affymax agreed to extend the Term of the Letter Agreement to December 31, 2005, and the subsequent Second Extension Letter dated as of December 19, 2005
between Affymax and EntreMed (the "Second
Extension Letter"), pursuant to which EntreMed and Affymax agreed to further extend the Term of the Letter Agreement to February 28, 2006. All capitalized terms used but not defined herein
shall have the meaning given to such terms in the Letter Agreement. 


        As
both parties would like to continue the Research Collaboration under the Letter Agreement, pending our current negotiations relating to a Co-Development Agreement, the
Term of the Letter Agreement is agreed to be further extended until May 31, 2006. Both Affymax and EntreMed acknowledge and agree that, except as otherwise set forth in herein, all terms and
conditions of the Letter Agreement, the First Extension Letter and the Second Extension Letter would remain unchanged and in full force and effect. 


        Please
confirm your agreement to extend the Term of the Letter Agreement (including, without limitation, the period to enter into a Co-Development Agreement) to
May 31, 2006, by countersigning this Letter and returning the countersigned letter to EntreMed. 



	 	 	Very truly yours,
	
 	
 	

EntreMed, Inc.
	
 	
 	

By:	

/s/ Marc Corrado
 Name: Marc Corrado

Title: VP, Corporate Development







	 ACCEPTED AND AGREED:	 	 
	
 Affymax, Inc.	
 	

 
	
 By:	

/s/ Christopher Dammann
 Name: Christopher Dammann

Title: V.P. Business Development

Date: March 1, 2006

	
 	

 




EntreMed,
Inc. / 9640 Medical Center Drive / Rockville, MD 20850

240.864.2600 phone / 240.864.2601 fax